Sabinsa's Curcumin C3 Complex(R) Subject of Recent Pancreatic Cancer Study

A recent University of Texas – MD Anderson Cancer Center study was published in the peer review American Association for Cancer Research's journal "Clinical Cancer Research" 14.14 (July 2008). Results of an eight-week human, phase II trial of the patented ingredient Curcumin C3 Complex(R) by Sabinsa, indicated orally-ingested curcumin is well-tolerated in pancreatic cancer patients and, despite limited absorption, curcuminoids showed biological efficacy in some patients with pancreatic cancer.

Titled "Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer," the peer-reviewed paper derives from a study that administered 8 grams of orally-ingested C3 Complex (as determined safe in phase I trials) daily to 25 patients, with thorough evaluation of disease progression over the two-month period. Markers for disease progression — notably inflammatory transcription factor nuclear factor-kappa B (NF-kappa B) and pro-inflammatory cyclooxygenase-2 (Cox-2) enzyme levels — were monitored in the 21 patients deemed reportable for treatment response. Results indicated that C3 Complex significantly lowered expression of disease biomarkers NF-kappa B and Cox-2. Two patients showed clinical biological activity. One had ongoing stable disease for over 18 months, and the other one had a brief, but marked, tumor regression (73 percent regression) accompanied by changed pattern in serum cytokines. No subjective or objective side effects were observed in the study.

"Pancreatic cancer remains one of the most fatal and short-prognosis cancers, with few available treatments for the disease, and virtually no overwhelmingly positive-result treatment," said Vladimir Badmaev, M.D., Ph.D., Sabinsa Corporation vice president of scientific and medical affairs and paper co-author. "Therefore, there is an urgent search for more effective and safe therapies. This study's experimental evidence indicates that increased expression of NF-kappa B contributes to rapid progression of pancreatic cancer, and that curcumin and its derivatives can suppresses NF-kappa B activation and slow down or inhibit progression of the cancer in some patients, despite limited absorption of curcumin."

For an electronic copy of the discussed paper, please contact Clint Curry at [email protected].

Sabinsa's Curcumin C3 Complex is an extract of turmeric roots standardized for 95 percent of phenolic compounds called curcuminoids. The same ground, dried roots of turmeric, which have been used for centuries as a spice (curry), food preservative and a coloring agent, have been found to be a rich source of phenolic compounds (curcuminoids) with versatile biological mechanisms. In the last three years alone there have been several pioneering IND (Investigational New Drug) studies granted by the FDA and other NIH funded studies for the investigation of C3 Complex in the treatment of patients with cancer, neurodegenerative diseases and diseases characterized by chronic inflammatory process.

Sabinsa Corporation is a manufacturer and supplier of herbal extracts, cosmeceuticals, minerals and specialty fine chemicals.
Celebrating its 20th year servicing the natural products industry, Sabinsa's mission is to provide alternative and complementary natural products for human nutrition and wellbeing. Over the past several years, the company has brought to market more than 50 standardized botanical extracts and privately funded several clinical studies in conjunction with prestigious institutions in support of these products. With more than 100 scientists working full time conducting ongoing research both in India and the United States, Sabinsa continues to develop and patent phytonutrients for the world market.

Sabinsa has six state-of-the-art manufacturing facilities in India dedicated to the production of herbal extracts, phytochemicals, biotech ingredients and supercritical extracts. In the U.S., the company operates a 42,000-square-foot facility in Payson, Utah, which provides cutting-edge capabilities for the development of capsules, tablets, bulk custom pre-mixes, drum-to-hopper blends, stick packs and powdered drinks. All of Sabinsa’s facilities use effluent water treatment systems and are environmentally conscious and friendly. All products are intended for human consumption and certified Kosher. For more information visit

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.